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Aggregation Characterization of Wild-Type p53 and Six Common 
p53 Mutants 
Taylor Arhar and Dr. David Moffet 
ABSTRACT: P53 is a tumor suppressor protein, which functions in maintaining the cell cycle. When p53 loses its function, cells 
may multiply at an uncontrolled rate and form tumors. This loss of function is linked to over fifty percent of human cancers. This 
investigation aims to explore the possible link between p53 aggregation and tumorigenesis. There is a possibility that p53, especial-
ly in mutant form, will aggregate beyond its normal tetrameric conformation and lose its function, leading to tumor formation. 
Wild-type p53 and six mutants, R175H, R175C, R248Q, R248W, R273C, and R273H (six of the most common mutations found in 
human cancers), were purified from E. coli using Ni-NTA agarose resin. Aggregation rates were monitored for the wild-type and 
each mutant by Thioflavin-T binding assays. Atomic force microscopy was used to visualize each of the p53 mutants pre-
incubation and at time points that Thioflavin-T binding suggested the presence of aggregates. Utilizing this data, each mutant was 
characterized for its relative speed of aggregation; this suggests which mutants are more aggregation-prone.  Combined with cell 
viability results, our data indicates that p53 aggregation of mutated variants is a contributing factor to tumorigensis.  Those mutants 
with the greatest propensity to aggregate also appear to be those with the greatest ability to become immortal.  
INTRODUCTION 
P53 is a critical tumor suppressor that regulates the cell cy-
cle.1 When the cell cycle is not regulated, cells multiply rapid-
ly and may become cancerous. The loss of p53 function, or 
cell cycle regulation, is linked to over 50% of human cancers.1 
In particular, there are known mutations of p53 that can lead to 
tumor formation. The mutation of p53 may cause mutant p53 
products to improperly fold;2 as protein function is vitally de-
pendent on the folded shape that proteins take, misfolding of 
proteins causes them to be dysfunctional. 
Generally, when proteins fold incorrectly, cellular machin-
ery breaks them down and gets rid of them as waste. However, 
in some diseases, such as Type II diabetes and Alzheimer’s, 
specific improperly folded proteins clump together instead of 
getting degraded. These clumps, or aggregates, are toxic to 
cells and are known as amyloid.3 As the toxic amyloid is 
found in these diseases, though it is not the definitive cause, 
the diseases are known as amyloid diseases. 
The question posed is whether or not the mutant strains of 
p53 aggregate to form toxic amyloid. Furthermore, by associa-
tion to p53 function, is tumor formation linked to the for-
mation of amyloid? Could cancer be a type of amyloid dis-
ease, when it is linked to loss of p53 function? The implica-
tions of this research are far-reaching; it links the fields of 
cancer and amyloid research and explores an aspect of tumor-
suppression that has little research currently published. If suc-
cessful, this research could identify causes for tumor for-
mation. 
As p53 has become a source of excitement in the scientific 
community, headlining for the March 2014 edition of Nature 
Reviews, it seems a fruitful protein to explore. In the last five 
years, aggregation of specific p53 domains have been charac-
terized, and it has been shown that p53 can gain toxicity in an 
aggregated state. P53 aggregates have even been found in 
breast tumors.3,4,5 What is missing is specific characterization 
of mutants of p53 that are commonly linked to cancers. This 
would enable a correlation between particular mutations and 
the process by which they cause tumor formation. 
This investigation aims to explore the possible link between 
p53 aggregation and tumorigenesis. There is a possibility that 
p53, especially in mutant form, will aggregate beyond its nor-
mal tetrameric conformation and lose its function, leading to 
tumor formation. Wild-type p53 and six mutants, R175H, 
R175C, R248Q, R248W, R273C, and R273H (six of the most 
common mutations found in human cancers), were purified 
from E. coli. Thioflavin-T binding assays were used to moni-
tor the aggregation rates of the wild-type and each mutant. 
Atomic force microscopy was used to visualize the p53 mu-
tants pre-incubation and at time points that Thioflavin-T bind-
ing suggested the presence of aggregates. Utilizing this data, 
each mutant was characterized for its relative speed of aggre-
gation; this suggests which mutants are more aggregation-
prone. 
METHODS 
2mL samples of Escherichia coli in which the p53 protein is 
expressed were grown in 500mL of LB Media in autoclaved 
Erlenmeyer flasks with 1 mL of Kanamycin.  The cultures 
were grown in a shaking incubator at 37 ˚C to an optical densi-
ty of A600 = ~0.6-0.8.  They were then rapidly cooled on ice 
for 5 minutes and inoculated with 5 mL of sterile filtered 
10mM IPTG in DI water.  The flasks were then grown over-
night in the shaking incubator at room temperature (approx. 
25˚C).  Following the overnight incubation, the cultures were 
pelleted in 500mL centrifuge bottles by spinning at 5000rpm 
for 15 minutes. The pellets were resuspended in 5 mL 50mM 
NaH2PO4 1M NaCl Buffer 1 and 1 mL B-PER. Each sample 
was then sonicated for four intervals of 30 seconds, followed 
by centrifugation at 5000rpm for 15 minutes. The pellets were 
resuspended in 10 mL Buffer 1 with 0.5% Triton X-100 and 
sonicated for two intervals of 30 seconds. After 15 minutes of 
centrifugation at 5000rpm, the pellets were resuspended in an 
inclusion body purification buffer of 8M urea, 0.1M Tris, 
1mM glycine, 1mM EDTA, 10mM DTT, 1mM reduced gluta-
thione, 10mM 2-mercaptoethanol, and 0.1% SDS. The sam-
ples were then sonicated for three intervals of 30 seconds and 
centrifuged at 5000rpm for 15 minutes. Finally, the superna-
tants were desalted into the original buffer. The samples were 
run on an SDS-PAGE gel and sterile filtered. Then a Thiofla-
vin-T assay was performed for each sample at 15 and 105 
minutes post-filtration, with shaking and incubation at 37˚C 
between time points. Samples were also visualized by atomic 
force microcroscopy at the 15 minute time point. 
 
RESULTS 
The wild-type and mutant p53 samples were visualized for 
relative purity on an SDS-PAGE gel, shown in Figure 1. 
Though each lane contains a number of protein bands, sug-
gesting impurity, it is visually clear that the majority of the 
protein present in solution is p53, suggested by the large, thick 
bands near 50 kDa band on the protein standard ladder. 
 
Figure 1. The SDS-PAGE gel shows the presence of high levels 
of p53 protein of relative purity. The lanes, from right to left: (1) 
Protein standard ladder (2) Wild-type p53 (3) R175C (4) R175H 
(5) R248Q (7) R248W (9) R273C (10) R273H. 
The results of the Thioflavin-T fluorescence assay are 
shown in Figure 2. High fluorescence indicates the presence of 
aggregates, and all p53 mutants showed higher fluorescence 
than the wild-type, with the exception of the R248W mutant. 
This suggests that the mutations to p53 do promote an increase 
in aggregation propensity. The higher fluorescence for each of 
the mutants at the first time point than the second time point 
suggests that the aggregation time point occurs between 15 
minutes and 105 minutes post-filtration. Compared to the 
wild-type, which showed increased fluorescence at the 105 
minute time point, the mutants reached the aggregation point 
more quickly, suggesting that the mutants form aggregates 
more quickly than the wild-type. Finally, from the varied max-
imum fluorescence values, it is clear that some mutants, spe-
cifically R273C, R273H, and R175H, have a higher propensity 
for aggregation than others. 
 
Figure 2. Thioflavin-T Fluorescence was measured at 488 nm at 
15 and 105 minutes post-filtration, with shaking and incubation at 
37˚C between time trials. High absorbance suggests the presence 
of aggregates. Note that all p53 mutants except R248W indicate 
higher propensity for aggregation than the wild-type p53. 
To confirm the results of the Thioflavin-T assays, atomic 
force microscopy was used to visualize each of the samples at 
the 15 minute time point. The images for the wild-type and the 
mutant R248Q are shown in Figure 3. The presence of white 
aggregates on the mutant slide confirms that the mutant has a 
higher propensity for aggregation than the wild-type, and also 
that Thioflavin-T accurately characterizes p53 aggregate for-
mation. 
 
Figure 3. Each panel shows the p53 at 15 minutes post filtration.  
Each sample was deposited onto a freshly cleaved mica slide and 
analyzed using tapping mode AFM in air.  (A) is wild-type p53. 
(B) is the p53 mutant R248Q. 
DISCUSSION 
The observed data from the purification and the analysis 
procedures are significant in several ways.  The initial at-
tempts to purify the protein were unsuccessful. It was deter-
mined that this was most likely due to the formation of inclu-
sion bodies during the purification steps.  The selection of the 
reagents in the purification buffer reflect this.  The buffer is 
designed to keep aggregation prone proteins soluble.  When 
the buffer was removed during the desalting steps, the solution 
visibly clouded, possibly due to the quick aggregation of the 
protein.  This evidence was supported by the high Thioflavin-
T fluorescence, even on initial readings.  Aggregation was also 
suggested by the visible aggregates on the AFM slides.  Com-
bined with cell viability results, the collected data indicates 
that p53 aggregation of mutated variants is a contributing fac-
tor to tumorigenesis.  Those mutants with the greatest propen-
sity to aggregate also appear to be those with the greatest abil-
ity to become immortal.  
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